Phase I/II study is tracking to meet primary endpoints RECCE ® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentration Cohort fully recruited with remaining subjects to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback